Latest Conference Articles

Stephen L. Hauser, MD: Increasing Understanding of Disease Progression in MS

Stephen L. Hauser, MD: Increasing Understanding of Disease Progression in MS

September 23rd 2020

ECTRIMS

The director of the UCSF Weill Institute for Neuroscience spoke to the advantages of having agents that can be used across the spectrum of MS, and the role disease progression plays early on.

Fatigue Plays a Key Factor in Multiple Sclerosis Daily Functioning

Fatigue Plays a Key Factor in Multiple Sclerosis Daily Functioning

September 23rd 2020

ECTRIMS

Patients with lower levels of disability tended to report fatigue as the most impactful symptom in daily life.

Luc Truyen, MD, PhD: Advantages of Ponesimod as an S1P Modulator

Luc Truyen, MD, PhD: Advantages of Ponesimod as an S1P Modulator

September 22nd 2020

ECTRIMS

The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical detailed what makes ponesimod different from other currently FDA-approved treatments.

Ocrelizumab Holds Benefit for Relapsing MS Patients With Prior Suboptimal DMT Response

Ocrelizumab Holds Benefit for Relapsing MS Patients With Prior Suboptimal DMT Response

September 22nd 2020

ECTRIMS

Treatment with ocrelizumab can improve freedom from individual events in patients with relapsing-remitting multiple sclerosis regardless of suboptimal DMT response in the past.

The Importance of Patient-Centered Care in Parkinson Disease

The Importance of Patient-Centered Care in Parkinson Disease

September 22nd 2020

MDS

The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers spoke to the importance of patient-focused interventions in PD.

Stephen L. Hauser, MD: Ofatumumab in Treatment-Naïve Patients With MS

Stephen L. Hauser, MD: Ofatumumab in Treatment-Naïve Patients With MS

September 22nd 2020

ECTRIMS

The director of the UCSF Weill Institute for Neuroscience offered his perspective on data presented at MS Virtual suggesting ofatumumab’s benefit in patients with MS who were treatment naïve.

Investigational Drug Targeting Epstein-Barr Virus Shows Promise for Progressive MS

Investigational Drug Targeting Epstein-Barr Virus Shows Promise for Progressive MS

September 21st 2020

ECTRIMS

Atara Biotherapeutics’ allogeneic EBV-targeted T-cell therapy, ATA188, is well-tolerated in phase 1, with a dose identified for the randomized placebo-controlled portion of the study.

Progressive and Relapsing-Remitting Multiple Sclerosis Share Similar Fatigue Severity

Progressive and Relapsing-Remitting Multiple Sclerosis Share Similar Fatigue Severity

September 21st 2020

ECTRIMS

Future research may help better characterize whether fatigue interventions aimed at one patient population may be effective in the other.

Ocrelizumab Treatment Results in High NEDA Rates, Improvements in MS Symptoms

Ocrelizumab Treatment Results in High NEDA Rates, Improvements in MS Symptoms

September 19th 2020

ECTRIMS

A pair of datasets from the phase 3b CASTING study of ocrelizumab (Ocrevus; Genentech) suggest that patients treated with the agent experienced high rates of no evidence of disease activity status regardless of prior DMT exposure.

Luc Truyen, MD, PhD: Long-Term Results of Ponesimod in Phase 2b Study

Luc Truyen, MD, PhD: Long-Term Results of Ponesimod in Phase 2b Study

September 18th 2020

ECTRIMS

The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical discussed the results of a phase 2 core and extension study of ponesimod in patients with relapsing-remitting multiple sclerosis.